Mirati Therapeutics (MRTX) Tops Q2 EPS by 13c, beats revenue

August 8, 2023 4:51 PM EDT

Mirati Therapeutics (NASDAQ: MRTX) reported Q2 EPS of ($3.04), $0.13 better than the analyst estimate of ($3.17). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $13.19 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities